ABIVAX (EPA:ABVX) EQS-News: Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
Transparency directive : regulatory news
|
EQS-News: ABIVAX
/ Key word(s): Miscellaneous
COMPANY STATEMENT Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution PARIS, France, March 13, 2023 – 12:00 p.m. (CET) – Abivax SA (the “Company”, Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, is aware that Silicon Valley Bank (“SVB”) was closed on March 10, 2023, by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. The Company does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution, and it does not have any banking relationship with SVB. The Company has no exposure to any liquidity concern at SVB or any other U.S. financial institution. ***** About Abivax (www.abivax.com) Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
13.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1580911 13.03.2023 CET/CEST